Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:27:02.152Z.
Calculation as of: 2026-10-06T15:27:02.152Z.
Quote observation: 2026-10-06T15:25:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cd3ead22764b77a02cf3e742533c366d0c9255af04c84535b20f2b2666bee2a
EARNINGS YIELD
N/A
Market Cap
$78.76M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.57M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$68.43M
Earnings Yield
130.20%
TTM Avg
107.81%
3Y Avg
107.81%
5Y Avg
107.81%
Market Cap
$68.77M
Earnings Yield
N/A
TTM Avg
4.28%
3Y Avg
4.21%
5Y Avg
1.79%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | $74.00M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.32M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $71.19M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $71.05M | N/A | 1.65% | 1.65% | 1.65% |
| Outset Medical, Inc. (OM)vs › | $77.48M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.57M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | 130.20% | 107.81% | 107.81% | 107.81% |
| Champions Oncology, Inc. (CSBR)vs › | $68.77M | N/A | 4.28% | 4.21% | 1.79% |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
